TPCA-1, >=95% (HPLC), powder
Application
TPCA-1 has been used to study its cytotoxic effects in RPMI8226 and LP1 cell lines. It has also been used as a culture media supplement for nuclear protein fractions extracted from human airway smooth muscle cells.
Biochem/physiol Actions
TPCA-1 is a potent and selective inhibitor of human IκB kinase-2 (IKK-2) with IC50 = 17.9 nM for IKK-2 compared to 400nm for IKK-1. It has been used to study inhibition of IKK-2 to prevent inflammatory mediator release in animal models of arthritis and airway inflammation.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
1, 5 mg in glass bottle
Preparation Note
TPCA-1 is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml. It is insoluble in water.
| Colour | white to light brown |
|---|---|
| Quality Level | 100 |
| InChI key | SAYGKHKXGCPTLX-UHFFFAOYSA-N |
| InChI | 1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18) |
| Manufacturer | SIGMA-ALDRICH |
| Form | powder |
| Assay | ≥95% (HPLC) |
There are no downloads for this product.
